48
In band
Moving averages
SMA 200$21.21-1.65%
Company profile
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The company's robust pipeline addresses critical unmet needs in mental health treatment, underscored by a commitment to innovative therapeutic solutions led by a seasoned management team. By harnessing its proprietary scientific approach, GH Research is strategically positioned to disrupt current treatment paradigms and enhance patient outcomes, establishing itself as a prospective leader in the rapidly evolving mental health therapeutics sector.
SectorHealthcare
IndustryBiotechnology
Market cap$1.37B
P/E ratioNone
EPS$-1.04
Beta1.325
Dividend yield0.00%
52-week high$31.44
52-week low$12.04
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 41
VRTX
Vertex Pharmaceuticals Inc
RSI 68
CRSP
CRISPR Therapeutics AG
RSI 48
IOVA
Iovance Biotherapeutics Inc
RSI 30
GPCR
Structure Therapeutics Inc
RSI 27
NTLA
Intellia Therapeutics Inc
RSI 53
SRPT
Sarepta Therapeutics Inc
RSI 51
ANRO
Alto Neuroscience Inc
RSI 40
NVAX
Novavax Inc
RSI 45
RXRX
Recursion Pharmaceuticals Inc - Class A
RSI 53
RSI alerts for GHRS
An email when GHRS closes below RSI 30 or above 70. Nothing else.
Add alertData last updated 13 October 2026 at 9:53 PM EDT